Avexa, a once-promising AU biotech has had a visit from the grim reaper. From .80 a few years go to .02 after the failure to secure a partner. The failure will remind some of Metabolic, although their drug simply bombed.
Hopefully some loyal Avexa holders (and there were many) will migrate over to CUV as they search for another biotech to spend on with what is left of their money.
With CXS taking a big hit this year, some will be shopping for a new AU biotech darling.
another one bites the dust
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.58 |
Change
-0.930(6.00%) |
Mkt cap ! $730.1M | |||
| Open | High | Low | Value | Volume |
| $15.35 | $15.74 | $14.23 | $4.173M | 285.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $14.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.58 | 1486 | 2 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |